ASTM E3351-22 PDF

Overview

ASTM E3351-22: Standard Test Method for Detection of Nitric Oxide Production In Vitro establishes a protocol for quantitatively measuring nitric oxide (NO) production by macrophages in response to nanomaterial exposure, using nitrite (NO₂⁻) levels as an indicator. The test is based on the colorimetric analysis of nitrite in cell culture media via the Griess reagent. This standardized method is a critical tool for assessing the immunological impact and biocompatibility of nanomaterials, with implications for biomedical research and product safety evaluation.

Nitric oxide is a key proinflammatory mediator generated by activated macrophages. Its overproduction can lead to cytotoxic effects, tissue injury, and is implicated in both normal physiological and pathological processes. By evaluating NO production in vitro, this standard aids researchers and manufacturers in predicting how nanomaterials might interact with biological systems during in vivo applications.

Key Topics

• Nitric Oxide Measurement: Quantifies NO by detecting nitrite, a stable end-product, after nanomaterial exposure.
• Murine Macrophage Model: Utilizes RAW 264.7 cell lines as an established in vitro model for immune response studies.
• Colorimetric Griess Assay: Employs the Griess reagent for reliable detection and measurement of nitrite in cell culture medium.
• Controls and Calibration: Incorporates strict calibration standards, quality controls, and acceptance criteria for reproducibility and data accuracy.
• Nanomaterial Interference: Addresses protocols for identifying and mitigating nanomaterial assay interference.
• Biological Relevance: Evaluates the proinflammatory and cytotoxic potential of nanomaterials, critical for biocompatibility assessments.
• Regulatory Alignment: Developed in accordance with international standards principles, supporting global harmonization.

Applications

This standard plays a pivotal role in multiple practical contexts:

• Preclinical Safety Assessment: Provides a standardized method for screening nanomaterials used in medical devices, pharmaceuticals, and drug delivery systems, helping to ensure product biocompatibility before in vivo studies.
• Nanotoxicology Research: Supports research into the immunomodulatory effects of engineered nanoparticles, helping scientists understand potential health risks and mechanisms of action.
• Product Development: Assists manufacturers in the development and validation of nanomaterial-based products, ensuring compliance with regulatory guidelines for safety.
• Regulatory Submissions: Facilitates the generation of robust, comparable NO production data to support submissions to health authorities and regulatory bodies.
• Academic Studies: Serves as a reference protocol for academic laboratories investigating aspects of inflammation, immune response, and nanoparticle-cell interactions.

Related Standards

Several related ASTM and international standards complement or support the use of ASTM E3351-22:

• ASTM E2490: Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Photon Correlation Spectroscopy (PCS)
• ASTM E2834: Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Nanoparticle Tracking Analysis (NTA)
• ASTM F1877: Practice for Characterization of Particles
• ASTM F1903: Practice for Testing for Cellular Responses to Particles In Vitro

These standards collectively offer a comprehensive framework for characterizing nanomaterials and assessing their biological interactions, supporting the rigorous evaluation of immune response, cytotoxicity, and overall biosafety in research and commercial applications.

Keywords: ASTM E3351-22, nitric oxide detection, nanomaterial biocompatibility, in vitro assay, macrophage response, Griess reagent, nanotoxicology, immune response, biomedical research, standard test method